Securities code: Lanzhou Foci Pharmaceutical Co.Ltd(002644) securities abbreviation: Lanzhou Foci Pharmaceutical Co.Ltd(002644) Announcement No.: 2022005 Lanzhou Foci Pharmaceutical Co.Ltd(002644) 2021 annual report summary
1、 Important note: the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should carefully read the full text of the annual report in the media designated by the CSRC. In addition to the following directors, other directors attended the meeting of the board of directors to consider the annual report in person
Name of director not present in person position of director not present in person reason for not attending the meeting name of the entrusted person
Director Shang Shoupeng was unable to attend Wang Yingchun on site due to physical reasons
Tips of non-standard audit opinions □ applicable √ not applicable to the profit distribution plan of common stock or the plan of converting accumulation fund into share capital in the reporting period reviewed by the board of directors √ applicable □ not applicable whether to convert accumulation fund into share capital □ yes √ no the company’s profit distribution plan of common stock reviewed and approved by the board of directors is: Based on 510657000, Distribute cash dividend of 0.10 yuan (including tax) to all shareholders for every 10 shares, and give bonus shares of 0 share (including tax), and do not use the accumulation fund to increase the share capital. Preferred stock profit distribution plan for the reporting period adopted by the board of directors □ applicable √ not applicable II. Basic information of the company 1. Company profile
Stock abbreviation Lanzhou Foci Pharmaceutical Co.Ltd(002644) stock code Lanzhou Foci Pharmaceutical Co.Ltd(002644)
Shenzhen Stock Exchange
Stock abbreviation before change (if any) none
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Li Baojun, Fu Jing
Office address: No. 2289, Huashan Road, Lanzhou New Area, Lanzhou City, Gansu Province
Fax: 09318362318
Tel: 09318362318
E-mail [email protected]. [email protected].
2. Introduction to main business or products during the reporting period
(I) main business of the company
The industry of the company is traditional Chinese medicine manufacturing. Its main business is the R & D, production and sales of Chinese patent medicine and big health products, the planting and sales of traditional Chinese medicine, the processing and sales of traditional Chinese medicine decoction pieces, and the production and sales of medical devices such as protective masks. The company has 467 drug approval numbers, produces more than 110 products in 11 dosage forms such as pills, tablets, granules, capsules and gels, and has 10 exclusive products such as Shenrong gubenhuanshao pills and Compound Huangqi Jianpi oral liquid. At present, the main products produced and sold by the company include Liuwei Dihuang pill, Xiaoyao Pill, Xiangsha Yangwei pill, Shenrong gubenhuanshao pill, donkey hide gelatin and other Chinese patent medicines, as well as traditional Chinese medicine decoction pieces and great health products, covering many categories and fields such as tonic, cold, gastrointestinal, gynecology, tranquilizing sleep and so on.
(II) business model of the company
The company’s business model is an all-round model of R & D, procurement, production and sales.
1. R & D mode
In 2021, focusing on the two main businesses of Chinese patent medicine manufacturing and big health product development, the company continued to increase investment in scientific research, actively carried out R & D work such as new product development, innovation platform construction and project application, and continuously improved the company’s technological innovation ability. We have carried out the development of a series of alternative tea products, actively planned the development and registration of cosmetic products and health care products, continuously expanded the company’s products and consolidated the foundation of product export. At the same time, we have deepened cooperation and exchanges with Lanzhou University, Shanghai University of traditional Chinese medicine, Chinese Academy of traditional Chinese medicine and other scientific research institutes. We have signed a contract with Lanzhou University to jointly build an innovative R & D Center for the whole industrial chain of modern traditional Chinese medicine. It plans to set up an enterprise research institute in Shanghai, gather high-quality scientific research experts, create a highland of R & D and innovation of traditional Chinese medicine products, and enhance the core competitiveness of the company.
2. Procurement mode
The company formulates procurement plans for raw materials, auxiliary materials and packaging materials according to the production plan, production tasks and the characteristics of the harvest season of traditional Chinese medicine. The procurement methods are public bidding and inquiry and price comparison procurement; The company carries out strict screening, evaluation and quality audit on suppliers, selects suppliers with stable supply quality, timely supply, high reputation and good service as strategic partners, and realizes the management mode of professional bidding procurement in combination with the collection and analysis of market information, so as to effectively reduce the company’s procurement cost on the basis of ensuring quality.
3. Production mode
The company adheres to market demand-oriented and organizes product production in strict accordance with GMP specifications. Enterprise resource planning runs through the whole production process chain, closely integrates internal resources of the enterprise, and realizes the optimization and sharing of resources and information. According to the annual sales forecast of each product and the decomposed monthly sales plan provided by the sales system, the production technology department shall formulate the production master plan for the variety, quantity, specification and progress requirements of the production products; Each production sub workshop strictly implements the production master plan, prepares the production plan of the workshop according to the material demand plan, process route, production resources and other elements, checks the matching degree between the material inventory, production capacity and the production plan, allocates materials and issues production instructions according to the task priority. The closed-loop control from planning to implementation is realized through workshop scheduling management. The quality management department shall do a good job in incoming material quality control, process quality control and finished product quality control, and conduct strict quality monitoring in key production links in the whole production process to effectively ensure product quality and safety.
4. Sales model
The sales mode of the company in the Chinese market is the combination of dealer distribution, direct supply sales of terminal chain pharmacies, market bidding of basic drugs and medical insurance products, fixed-point distribution sales and agent sales. At present, the foreign market mainly adopts the cooperative sales mode. The company continues to deepen the reform of the marketing system, actively introduces professional managers and top consulting and planning companies in the industry, and comprehensively improves the marketing ability and brand influence by comprehensively building and combing the marketing channels, sales policies, marketing organization and product positioning.
(III) operation in 2021
2021 coincides with the 100th anniversary of the founding of the Communist Party of China and the beginning of the 14th five year plan. It is an extraordinary year in the development process of the company. In the face of multiple pressures in the post epidemic era, such as economic downturn, blocked circulation and deepening pharmaceutical system reform, the company faced the challenges and continued to promote the multi-dimensional improvement of sales, R & D, production and management. During the reporting period, guided by the thought of Xi Jinping new era socialism with Chinese characteristics, the Party committee of the company thoroughly implemented the spirit of the 19th CPC National Congress and all previous plenary sessions of the 19th CPC National Congress, withstood the pressure, united as one, implemented the strategic plan, took the initiative, optimized the market layout, paid close attention to internal management, and better completed various objectives and tasks set at the beginning of the year. During the reporting period, the company achieved an operating income of 8176408 million yuan, an increase of 22.39% over the same period of last year; The net profit attributable to shareholders of listed companies was 93.259 million yuan, a decrease of 13.66% over the same period last year.
First, fully implement the company’s strategic plan. In accordance with the three wheel drive development strategy of “operation driven, innovation driven and financial driven” and the six ecosystem construction plan of “large industry, large production, large market, large brand, large research and development and large capital”, the company focuses on the main responsibility and main business, continues to supplement and extend the chain, and determines the Chinese patent medicine manufacturing and large health industry as the two main businesses of the company. The strategic plan of the company is clearer, The strategic layout will be improved.
Second, the scientific management level has been continuously improved. Revise and improve the list of rights and responsibilities of the “three meetings and one level” and the rules of procedure of the Party committee, the shareholders’ meeting, the board of directors, the board of supervisors and the management level, so as to ensure clear rights and responsibilities, standardized decision-making and strong development. Comprehensively implement the excellent performance management mode, revise and improve 209 management systems in combination with the special treatment activity of “running, emitting, dripping and leaking”, deeply implement 6S management in the workshop, and gradually implement amoeba business mode in the subsidiary, so as to lay a solid foundation for the high-quality development of the company.
Third, innovative marketing to enhance brand influence. In 2021, members of the company’s leadership team focused on the market, introduced a team of marketing professional managers, and comprehensively improved the marketing ability and brand influence of foci with a point, line and surface marketing system. In the whole year, 164 direct supply chains, 321 prefecture level city chains, 121 medical channels, 29 agency channels and 68 commercial channels were newly developed. The OTC market coverage of foci’s full range of products reached 70%; Brand influence has been steadily improved.
Fourth, the fight against the epidemic has won social praise. Since the outbreak of a new round of covid-19 pneumonia in Lanzhou, Lanzhou Foci Pharmaceutical Co.Ltd(002644) took the initiative to assume the responsibility of state-owned enterprises. According to the unified deployment of the Municipal Health Commission, the Fuci science and Technology Industrial Park in Lanzhou New Area has implemented closed management and worked overtime for 24 hours. It has spared no effort to produce epidemic prevention Decoction “Qihuang anti plague formula, Xuanfei Huazhuo Decoction” and medical protective masks, and has produced more than 574000 bags of decoction, all kinds of medical 3.4 million civilian masks. Go all out to do a good job in the procurement and allocation of epidemic prevention drugs and instruments, strictly manage and put them in order, adhere to maintaining the price stability of epidemic prevention supplies, and interpret the responsibilities and responsibilities of foci medicine. At the same time, the company donated more than 6 million yuan of epidemic prevention materials to schools, airports, traffic police, urban management and other departments through Lanzhou Red Cross Society, which contributed to the “Buddha kindness” force to win the war of epidemic prevention and control. 3. Main accounting data and financial indicators (1) whether the company needs to retroactively adjust or restate the accounting data of previous years in recent three years √ yes □ no retroactively adjust or restate the reasons for accounting error correction
Unit: Yuan
At the end of 2020, the end of this year is higher than that at the end of 2019 of last year
Increase or decrease at the end of 2021
Before adjustment, after adjustment, before adjustment, after adjustment.
Total assets 23520937092,267132,508. 2,387181,792. – 1.47% 2,314892,098. 2,400686,966. 48 63 19 40 23
Net assets attributable to shareholders of listed companies 16145770621,591159,687. 1,582090,699. 2.05% 1,510002,283. 71,10701882 37 97 92 58
In 2020, this year increased by 2019 over the previous year
Less in 2021
Before adjustment, after adjustment, before adjustment, after adjustment.
Operating income 81764082606680510139266805101392 22.39% 6288151640762881516407 2
Net profit attributable to shareholders of listed companies 93258956071119810400010801796691 – 13.66% 74852560497110701882
Net profit attributable to shareholders of listed companies after deducting non 429285481718731623701476855061 190.68% – 96198656 – 470752823 recurring profits and losses
Net cash flow from operating activities 118546424462888162806288816280 – 81.15% 47822985374782298537
